Development of novel adoptive cell therapy using antigen receptor engineering T cells for chemo/radiotherapy-resistant esophageal cancer

我们对临床试验患者接受TCR(T细胞受体)基因转导的淋巴细胞的样本进行了分析，并利用小鼠模型研究了肿瘤特异性淋巴细胞的过继细胞治疗。在临床试验患者中，在他们的外周血中检测到TCR转导的淋巴细胞约占PBMC的1%。输注的细胞在所有患者体内存活长达10个月。在TCR转基因小鼠过继细胞治疗模型中，CD4+T细胞或整合素信号的存在提高了CD8+T细胞的多功能性，增强了抗肿瘤作用。此外，我们已经基本建立了TCR基因转导的淋巴细胞过继转移的小鼠模型。

We performed analysis of samples from the clinical trail patients administrated TCR(T cell receptor)-gene transduced lymphocytes and researched on adoptive cell therapy of tumor-specific lymphocytes using mouse model. In the clinical trail patients, TCR-transduced lymphocytes were detected in their peripheral blood as approximately 1% of PBMC. The infused cells have been in vivo persisted in all patients as long as 10 months. In the adoptive cell therapy model of TCR transgenic mouse, presence of CD4+ T cells or integrin signals is elevated CD8+ T cell multifunctionality, and enhanced anti-tumor effect. Furthermore, we have almost established mouse model of the adoptive transfer of TCR-gene transduced lymphocytes.